Recommendations look to bring needed imaging equipment to facilities faster.
With the growing need for medical imaging to manage patients with COVID-19 infection, the Medical Imaging & Technology Alliance (MITA) asked the U.S. Food & Drug Administration (FDA) earlier this month to offer some regulatory flexibility that will make it easier for manufacturers to make needed equipment more quickly available.
“The COVID-19 pandemic poses an unprecedented health challenge. Medical imaging is playing an important role helping scientists and physicians better understand and confront COVID-19,” said Dennis Durmis, chair of the MITA Board of Directors. “Mobile imaging is a key component in responding where the crisis is most acute and imaging manufacturers are working with the FDA and other key agencies to increase the availability of medical imaging equipment where it is most needed.”
To hasten the arrival of these tools in the clinical environment, MITA has requested the FDA:
While none of these measures would impact the safety and efficacy of medical imaging devices, Durmis said, acting on these recommendations would make it easier to deliver vital medical imaging equipment during a time when need is critical.